Verizon delivers extra value with free safety, family and AI perks Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
Marks 29 Patents Worldwide Directed to Biora’s Device Localization Technology SAN DIEGO, May 19, 2022…
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning…
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation…
Accelus Receives U.S. FDA 510(k) Clearance for its Toro-L Interbody Fusion System
Toro Lateral (Toro-L) Interbody Fusion System Accelus announced today that it had received U.S. FDA…
Yield10 Bioscience to Present at the H.C. Wainwright Global Hybrid Investment Conference
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or…
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022…
Kane Biotech to Release First Quarter 2022 Financial Results on May 26 – Conference Call to Follow
WINNIPEG, Manitoba, May 19, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a…
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase…
Tricida Announces Administrative Stop of the VALOR-CKD Trial
Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 SOUTH SAN FRANCISCO,…
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing…
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring…
Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years
Randomized Disrupt PAD III Study Finds Superior Vessel Preparation Leads to Excellent Long-Term Outcomes and…
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER,…
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual…
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a…
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR),…
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3…
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected…